Earnings summaries and quarterly performance for Sotera Health.
Executive leadership at Sotera Health.
Board of directors at Sotera Health.
AK
Ann Klee
Detailed
Director
CS
Christopher Simon
Detailed
Director
CM
Constantine Mihas
Detailed
Director
DW
David Wheadon
Detailed
Director
JN
James Neary
Detailed
Director
KF
Karen Flynn
Detailed
Director
RK
Robert Knauss
Detailed
Director
RC
Ruoxi Chen
Detailed
Director
SC
Sean Cunningham
Detailed
Director
VP
Vincent Petrella
Detailed
Lead Independent Director
Research analysts who have asked questions during Sotera Health earnings calls.
Michael Polark
Wolfe Research
7 questions for SHC
Also covers: BBNX, BSX, DXCM +13 more
Patrick Donnelly
Citi
7 questions for SHC
Also covers: A, AVTR, BIO +24 more
DW
David Windley
Jefferies Financial Group Inc.
6 questions for SHC
Also covers: CERT, CNC, CRL +15 more
Jason Bednar
Piper Sandler Companies
6 questions for SHC
Also covers: ALGN, COO, EDAP +17 more
Brett Fishbin
KeyBanc Capital Markets
5 questions for SHC
Also covers: ALC, COO, ICUI +7 more
CW
Casey Woodring
JPMorgan Chase & Co.
5 questions for SHC
Also covers: A, AVTR, BLLN +15 more
Luke Sergott
Barclays
4 questions for SHC
Also covers: A, AVTR, BRKR +20 more
Sean Dodge
RBC Capital Markets
4 questions for SHC
Also covers: BTSG, CDMO, CTLT +14 more
BF
Brett Fishman
KeyBanc Capital Markets Inc.
2 questions for SHC
Also covers: ITGR, LIVN, SOLV
Christine Rains
William Blair
2 questions for SHC
Also covers: CERT, CRL, ICLR +3 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for SHC
Also covers: A, ADPT, AVTR +21 more
RH
Ryan Halsted
RBC Capital Markets
2 questions for SHC
Also covers: DOCS, EVH, WAY
Sam Eiber
BTIG, LLC
2 questions for SHC
Also covers: AIRS, APYX, EMBC +8 more
Dave Windley
Jefferies LLC
1 question for SHC
Also covers: CERT, CNC, CRL +8 more
Recent press releases and 8-K filings for SHC.
Sotera Health Reports Strong Full Year 2025 Results and Provides 2026 Outlook
SHC
Earnings
Guidance Update
Management Change
- Sotera Health reported full year 2025 revenue of $1.164 billion, an increase of 5.7% (5.2% constant currency), and adjusted EBITDA of $593.8 million, up 8.2% (7.8% constant currency), with adjusted EPS of $0.86 and adjusted free cash flow of $210 million.
- For 2026, the company expects total revenue between $1.233 billion and $1.251 billion (5%-6.5% constant currency growth) and adjusted EBITDA between $632 million and $641 million (5.5%-7% constant currency growth), with adjusted EPS in the range of $0.93-$1.01.
- The company improved its net leverage to 3.2x at year-end 2025 from 3.7x in 2024 and paid down $86 million of debt, resulting in $13 million of annual interest savings.
- Alex Dimitrief will transition from Senior Vice President and General Counsel to an outside advisor, effective April 1st, with Erika Ostrowski promoted to Senior Vice President and General Counsel.
4 days ago
Sotera Health Reports Strong 2025 Performance and Issues 2026 Outlook
SHC
Earnings
Guidance Update
New Projects/Investments
- Sotera Health reported a strong 2025, with total company revenue increasing 5.7% to $1.164 billion and Adjusted EBITDA growing 8.2%, with margins expanding to 51%. The company also delivered adjusted free cash flow of over $200 million.
- For 2026, the company issued guidance expecting total revenue in the range of $1.233 billion-$1.251 billion (5%-6.5% constant currency growth) and adjusted EBITDA between $632 million-$641 million (5.5%-7% constant currency growth). Adjusted EPS is projected to be in the range of $0.93-$1.01.
- In 2025, Sotera Health significantly improved its financial position by paying down $86 million of debt, increasing liquidity by $175 million, and reducing net leverage to 3.2x at year-end from 3.7x in 2024.
- Operational highlights include Sterigenics' approximately 8% constant currency revenue growth and Nordion's approximately 9% constant currency revenue growth in 2025. The company is also progressing with the construction of a new X-ray facility, which is planned to open in 2026.
4 days ago
Sotera Health Announces Q4 and Full-Year 2025 Results, Provides 2026 Outlook
SHC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Sotera Health reported Q4 2025 Net Revenues of $303,441 thousand, Adjusted EBITDA of $157,037 thousand, and Adjusted Diluted EPS of $0.26.
- For the full year 2025, the company achieved Net Revenues of $1,163,617 thousand, Adjusted EBITDA of $593,801 thousand, Adjusted Diluted EPS of $0.86, and Free Cash Flow of $209,853 thousand.
- The Net Leverage Ratio as of December 31, 2025, was 3.2x, which is on track with the 2.0x - 3.0x Investor Day target.
- For 2026, Sotera Health anticipates Net Revenues between $1,233 million and $1,251 million, Adjusted EBITDA between $632 million and $641 million, and Adjusted EPS between $0.93 and $1.01. Capital expenditures are projected to be $175 million to $225 million.
4 days ago
Sotera Health Reports Strong Full-Year 2025 Results and Issues Positive 2026 Outlook
SHC
Earnings
Guidance Update
New Projects/Investments
- Sotera Health reported full-year 2025 revenue of $1.164 billion, a 5.7% increase, with adjusted EBITDA growing 8.2% to $593.8 million and margins expanding to 51%.
- For 2026, the company expects total revenue to range from $1.233 billion to $1.251 billion (representing 5%-6.5% constant currency growth) and adjusted EBITDA from $632 million to $641 million (representing 5.5%-7% constant currency growth), with adjusted EPS between $0.93 and $1.01.
- In 2025, Sotera Health delivered $210 million in adjusted free cash flow and reduced $86 million of debt, improving its net leverage ratio to 3.2x at year-end.
- The company is progressing with its long-term strategic investments, including the planned opening of a new X-ray facility in 2026.
4 days ago
Sotera Health Company Reports Strong 2025 Results and Provides 2026 Outlook
SHC
Earnings
Guidance Update
Management Change
- Sotera Health Company reported full-year 2025 net revenues of $1.164 billion, an increase of 5.7% from 2024, marking its 20th consecutive year of revenue growth.
- For full-year 2025, net income increased to $78 million ($0.27 per diluted share) and Adjusted EBITDA grew 8.2% to $594 million.
- The company provided a full-year 2026 outlook projecting net revenues between $1.233 billion and $1.251 billion and Adjusted EBITDA between $632 million and $641 million.
- As of December 31, 2025, Sotera Health's Net Leverage Ratio improved to 3.2x from 3.7x in 2024, with $345 million in cash and cash equivalents.
- Erika Ostrowski will be promoted to Senior Vice President and General Counsel, effective April 1, 2026.
4 days ago
Sotera Health Provides Business Overview and Financial Targets
SHC
Guidance Update
Revenue Acceleration/Inflection
Debt Issuance
- Sotera Health is a global leader in sterilization and lab testing, with 70%+ of revenue tied to multi-year contracts and a diversified business across three segments: Sterigenics, Nordion, and Nelson Labs.
- The company has delivered sustained revenue growth for over 20 years, achieving a 9% CAGR since 2005.
- For the 2025-2027 period, Sotera Health targets an Organic Revenue Growth CAGR of 5% - 7% and an Organic Adjusted EBITDA Growth CAGR of 5-8%, along with a margin improvement target of 50-150bps.
- As of September 30, 2025, the company reported Net Revenues of $860,176 thousand and Adjusted EBITDA of $436,764 thousand for the nine months ended, with a Net Leverage Ratio of 3.3x.
- Sotera Health is on track with its Investor Day commitments as of September 30, 2025, including achieving 6.2% organic revenue growth and 10.4% Adjusted EBITDA growth year-to-date.
Jan 12, 2026, 6:30 PM
Sotera Health Provides Business Update at J.P. Morgan Healthcare Conference
SHC
Guidance Update
Revenue Acceleration/Inflection
Legal Proceedings
- Sotera Health (SHC) expects 2025 revenues to surpass $1.16 billion , aligning with its long-term guidance (2025-2027) of 5%-7% top-line growth and 5%-8% Adjusted EBITDA growth.
- Through Q3 2025, the company achieved 6.2% organic growth, 10.4% Adjusted EBITDA growth, and 195 basis points of margin improvement.
- The capital structure has improved, with net leverage reduced by one turn to 3.3 times and debt maturity extended to 2031.
- Improving demand is noted in the Sterigenics business, with inventory issues largely resolved across most med device and pharma categories.
- Favorable legal outcomes in Georgia led to the dismissal of bellwether cases , and one significant customer plans to outsource sterilization to SHC, with effects anticipated from late 2026 into 2027-2028.
Jan 12, 2026, 6:30 PM
Sotera Health Provides 2025 Revenue Update and Long-Term Outlook
SHC
Guidance Update
Legal Proceedings
New Projects/Investments
- Sotera Health expects 2025 revenue to surpass $1.16 billion, reflecting over 5% growth, with all three businesses performing well in Q4 2025.
- The company reaffirmed its long-term guidance for 5%-7% top-line growth and 5%-8% EBITDA growth from 2025 through 2027, with organic growth tracking at 6.2% through Q3 2025.
- Sotera Health anticipates 3%-4% price increases for the total company in 2026 and is expanding capacity with an X-ray facility opening in 2026 and cobalt development programs expecting first harvest in 2028.
- In legal proceedings, three bellwether cases in Georgia were dismissed due to lack of causation, and the company is confident in its defense for California trials scheduled for January 2027 and April 2027.
Jan 12, 2026, 6:30 PM
Sotera Health Provides Business Update and Financial Outlook
SHC
Guidance Update
New Projects/Investments
Legal Proceedings
- Sotera Health announced that 2025 revenue surpassed $1.16 billion, reflecting over 5% growth.
- The company is on track with its 2025-2027 long-range guide, reporting 6.2% organic growth, 10.4% adjusted EBITDA growth, and 195 basis points of margin improvement through Q3 2025, with a target of $500 million-$600 million in cumulative free cash flow over the period.
- Capital structure has improved, with the net leverage ratio at 3.3 times and debt maturity extended to 2031.
- Significant investments are underway for Cobalt-60 development, with the first harvest expected in 2028, and new Sterigenics greenfield facilities opening in 2026 and late 2027/early 2028.
- Ethylene oxide regulations (NESHAP) have been extended to April 2028, and favorable rulings in Georgia resulted in the dismissal of three bellwether cases, while California litigation trials are set for January and April 2027.
Jan 12, 2026, 6:30 PM
Sotera Health provides preliminary 2025 revenue guidance
SHC
Earnings
Guidance Update
- Sotera Health expects its full-year 2025 revenue to surpass $1.16 billion, representing an increase of at least 5.5% year over year, or 5.0% on a constant-currency basis.
- This projected revenue growth would mark over two decades of year-over-year revenue growth for the company.
- The company plans to release its full-year 2025 results and 2026 outlook on February 24, 2026.
- These financial figures are preliminary estimates and are subject to the completion of year-end closing procedures and audit.
Jan 12, 2026, 12:24 PM
Quarterly earnings call transcripts for Sotera Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more